Stock GILD GILEAD SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
65.42 USD +0.23% Intraday chart for Gilead Sciences, Inc. -2.01% -19.24%
04-26 TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90 MT
04-26 Jefferies Adjusts Gilead Sciences' Price Target to $80 From $95 MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 82,209 73,031 91,081 107,677 100,942 81,577 - -
Enterprise Value (EV) 1 82,450 103,910 118,530 126,522 118,665 98,461 90,862 85,349
P/E ratio 15.4 x 583 x 14.7 x 23.6 x 18 x 140 x 12.4 x 11.6 x
Yield 3.88% 4.67% 3.91% 3.4% 3.7% 4.75% 4.96% 5.16%
Capitalization / Revenue 3.66 x 2.96 x 3.34 x 3.95 x 3.72 x 2.96 x 2.91 x 2.84 x
EV / Revenue 3.67 x 4.21 x 4.34 x 4.64 x 4.38 x 3.57 x 3.25 x 2.97 x
EV / EBITDA 6.61 x 7.88 x 8.12 x 8.86 x 9.01 x 10.3 x 6.51 x 6.03 x
EV / FCF 9.91 x 13.8 x 11 x 15.2 x 16 x 11.3 x 9.69 x 8.66 x
FCF Yield 10.1% 7.24% 9.12% 6.59% 6.25% 8.84% 10.3% 11.6%
Price to Book 3.65 x 4.04 x 4.32 x 5.05 x 4.48 x 3.55 x 3.15 x 2.81 x
Nbr of stocks (in thousands) 1,265,146 1,253,528 1,254,384 1,254,244 1,246,042 1,246,969 - -
Reference price 2 64.98 58.26 72.61 85.85 81.01 65.42 65.42 65.42
Announcement Date 20-02-04 21-02-04 22-02-01 23-02-02 24-02-06 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 22,449 24,689 27,305 27,281 27,116 27,548 27,994 28,724
EBITDA 1 12,468 13,184 14,598 14,283 13,177 9,521 13,968 14,144
EBIT 1 11,064 11,704 12,548 12,180 10,484 7,324 11,628 12,049
Operating Margin 49.29% 47.41% 45.95% 44.65% 38.66% 26.59% 41.54% 41.95%
Earnings before Tax (EBT) 1 5,160 1,669 8,278 5,814 6,859 1,487 8,600 8,995
Net income 1 5,386 123 6,225 4,592 5,665 437.4 6,480 6,909
Net margin 23.99% 0.5% 22.8% 16.83% 20.89% 1.59% 23.15% 24.05%
EPS 2 4.220 0.1000 4.930 3.640 4.500 0.4678 5.280 5.618
Free Cash Flow 1 8,319 7,518 10,805 8,344 7,421 8,702 9,381 9,858
FCF margin 37.06% 30.45% 39.57% 30.59% 27.37% 31.59% 33.51% 34.32%
FCF Conversion (EBITDA) 66.72% 57.02% 74.02% 58.42% 56.32% 91.39% 67.16% 69.7%
FCF Conversion (Net income) 154.46% 6,112.2% 173.57% 181.71% 131% 1,989.34% 144.78% 142.69%
Dividend per Share 2 2.520 2.720 2.840 2.920 3.000 3.106 3.246 3.376
Announcement Date 20-02-04 21-02-04 22-02-01 23-02-02 24-02-06 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 7,421 7,244 6,590 6,260 7,042 7,389 6,352 6,599 7,051 7,115 6,686 6,729 6,991 7,247 6,487
EBITDA 1 4,902 2,042 4,049 3,195 3,811 3,227 2,883 3,258 3,908 3,427 -889.3 3,349 3,384 3,555 -
EBIT 1 4,379 1,507 3,524 2,670 3,286 2,699 2,243 2,277 3,224 2,739 -1,117 2,675 2,893 2,912 2,605
Operating Margin 59.01% 20.8% 53.47% 42.65% 46.66% 36.53% 35.31% 34.51% 45.72% 38.5% -16.71% 39.76% 41.39% 40.19% 40.15%
Earnings before Tax (EBT) 3,438 759 -152 1,503 2,432 2,031 1,300 1,588 2,318 1,653 -4,486 1,796 2,215 2,170 2,025
Net income 1 2,592 382 19 1,144 1,789 1,640 1,010 1,045 2,180 1,429 -4,170 1,444 1,654 1,634 1,562
Net margin 34.93% 5.27% 0.29% 18.27% 25.4% 22.2% 15.9% 15.84% 30.92% 20.08% -62.37% 21.46% 23.65% 22.55% 24.08%
EPS 2 2.050 0.3000 0.0200 0.9100 1.420 1.300 0.8000 0.8300 1.730 1.140 -3.340 1.141 1.289 1.303 1.160
Dividend per Share 2 0.7100 0.7100 0.7300 0.7300 0.7300 0.7300 0.7500 0.7500 0.7500 0.7500 0.7700 0.7700 0.7700 0.7700 0.7633
Announcement Date 21-10-28 22-02-01 22-04-28 22-08-02 22-10-27 23-02-02 23-04-27 23-08-03 23-11-07 24-02-06 24-04-25 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 241 30,879 27,449 18,845 17,723 16,885 9,285 3,772
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 0.0193 x 2.342 x 1.88 x 1.319 x 1.345 x 1.773 x 0.6648 x 0.2667 x
Free Cash Flow 1 8,319 7,518 10,805 8,344 7,421 8,702 9,381 9,858
ROE (net income / shareholders' equity) 38.3% 43.8% 46.8% 43.3% 38.5% 21.3% 35.9% 32.5%
ROA (Net income/ Total Assets) 8.6% 0.19% 9.13% 14% 13.5% 7.73% 12.9% 12.8%
Assets 1 62,651 65,079 68,180 32,874 41,980 5,657 50,305 53,772
Book Value Per Share 2 17.80 14.40 16.80 17.00 18.10 18.40 20.70 23.30
Cash Flow per Share 2 7.160 6.470 9.020 7.190 6.360 3.300 7.730 8.430
Capex 1 825 650 579 728 585 698 705 714
Capex / Sales 3.67% 2.63% 2.12% 2.67% 2.16% 2.53% 2.52% 2.48%
Announcement Date 20-02-04 21-02-04 22-02-01 23-02-02 24-02-06 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Gilead Sciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
65.42 USD
Average target price
84.25 USD
Spread / Average Target
+28.78%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
GILEAD SCIENCES, INC. Stock Gilead Sciences, Inc.
-19.24% 81.58B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. Financials Gilead Sciences, Inc.